clinical trials, industry

Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

Science-based tinnitus therapeutics are finally coming into their own.

Conflicts of interest among institutional review board members are disclosed more often than they were a decade ago, according to a survey of academics.

The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.

The $6 billion deal marks yet another massive transaction in the health-care industry.

At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.

Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.

A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.

Whether working for a pharmaceutical giant or a biotech start-up with a unique vision, researchers who responded to this year’s Best Places to Work in Industry survey are translating society’s most pressing scientific needs into a new generation of drugs, research tools, and cutting-edge innovations.

Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.